New hope for advanced breast cancer: drug combo aims to halt tumor growth
NCT ID NCT07235618
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding entinostat to fulvestrant can help control advanced breast cancer in people whose disease has worsened after standard hormone therapy and CDK4/6 inhibitors. About 50 women aged 18-75 with HR+/HER2- cancer will receive the combination. The main goal is to see how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug YL202 targets Hard-to-Treat breast cancers
- Real-world data may reveal true effectiveness of leading breast cancer therapy
- Simple gloves and socks may shield breast cancer patients from chemo nerve pain
- New drug combo shows promise for Hard-to-Treat breast cancer
- New pill combo aims to fight Hard-to-Treat breast cancer
- Real-world data on palbociclib combo for breast cancer in japan